BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 22593176)

  • 21. Applications of Flow Cytometric Immunophenotyping in the Diagnosis and Posttreatment Monitoring of B and T Lymphoblastic Leukemia/Lymphoma.
    DiGiuseppe JA; Wood BL
    Cytometry B Clin Cytom; 2019 Jul; 96(4):256-265. PubMed ID: 31231940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
    Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
    Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
    Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
    Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
    Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
    Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunoglobulin and T-cell receptor gene rearrangement and expression in human lymphoid leukemia cells at different stages of maturation.
    Davey MP; Bongiovanni KF; Kaulfersch W; Quertermous T; Seidman JG; Hershfield MS; Kurtzberg J; Haynes BF; Davis MM; Waldmann TA
    Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8759-63. PubMed ID: 3464980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
    Kotrova M; Trka J; Kneba M; Brüggemann M
    Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical benefit of a high-throughput sequencing approach for minimal residual disease in acute lymphoblastic leukemia.
    Wright G; Watt E; Inglott S; Brooks T; Bartram J; Adams SP
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27787. PubMed ID: 31034760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
    Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
    BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
    Pongers-Willemse MJ; Seriu T; Stolz F; d'Aniello E; Gameiro P; Pisa P; Gonzalez M; Bartram CR; Panzer-Grümayer ER; Biondi A; San Miguel JF; van Dongen JJ
    Leukemia; 1999 Jan; 13(1):110-8. PubMed ID: 10049045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of clonal stability of minimal residual disease targets between 1st and 2nd relapse of childhood precursor B-cell acute lymphoblastic leukemia.
    Guggemos A; Eckert C; Szczepanski T; Hanel C; Taube T; van der Velden VH; Graf-Einsiedel H; Henze G; Seeger K
    Haematologica; 2003 Jul; 88(7):737-46. PubMed ID: 12857551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the T-cell receptor beta chain repertoire in tumor-infiltrating lymphocytes.
    Nakanishi K; Kukita Y; Segawa H; Inoue N; Ohue M; Kato K
    Cancer Med; 2016 Sep; 5(9):2513-21. PubMed ID: 27465739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel analysis of minimal residual disease in leukemia with TCR beta rearrangement--detection of monoclonality by single strand conformation polymorphism and PCR using a clonotype primer of leukemic T cell receptor beta-chain RNA.
    Hanawa H; Koike T; Sakaue M; Kishi K; Shibata A; Abo T
    Leuk Res; 1997 Mar; 21(3):201-10. PubMed ID: 9111164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selection.
    Theunissen PMJ; de Bie M; van Zessen D; de Haas V; Stubbs AP; van der Velden VHJ
    Leuk Res; 2019 Jan; 76():98-104. PubMed ID: 30389174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.
    Logan AC; Gao H; Wang C; Sahaf B; Jones CD; Marshall EL; Buño I; Armstrong R; Fire AZ; Weinberg KI; Mindrinos M; Zehnder JL; Boyd SD; Xiao W; Davis RW; Miklos DB
    Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21194-9. PubMed ID: 22160699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring.
    Germano G; del Giudice L; Palatron S; Giarin E; Cazzaniga G; Biondi A; Basso G
    Leukemia; 2003 Aug; 17(8):1573-82. PubMed ID: 12886245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterisation of non-concordance in the T-cell receptor gamma chain genes at presentation and clinical relapse in acute lymphoblastic leukemia.
    Taylor JJ; Rowe D; Kylefjord H; Chessells J; Katz F; Proctor SJ; Middleton PG
    Leukemia; 1994 Jan; 8(1):60-6. PubMed ID: 8289500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia.
    Brüggemann M; van der Velden VH; Raff T; Droese J; Ritgen M; Pott C; Wijkhuijs AJ; Gökbuget N; Hoelzer D; van Wering ER; van Dongen JJ; Kneba M
    Leukemia; 2004 Apr; 18(4):709-19. PubMed ID: 14961040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resolving T-cell receptor clonality in two and genotype in four multiplex polymerase chain reactions.
    Dictor M; Warenholt J; Isinger A
    Haematologica; 2005 Nov; 90(11):1524-32. PubMed ID: 16266900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
    Dibenedetto SP; Lo Nigro L; Mayer SP; Rovera G; Schilirò G
    Blood; 1997 Aug; 90(3):1226-32. PubMed ID: 9242556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Annotation of pseudogenic gene segments by massively parallel sequencing of rearranged lymphocyte receptor loci.
    Dean J; Emerson RO; Vignali M; Sherwood AM; Rieder MJ; Carlson CS; Robins HS
    Genome Med; 2015 Nov; 7():123. PubMed ID: 26596423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.